Last €14.30 EUR
Change Today -0.15 / -1.04%
Volume 14.7K
REG1V On Other Exchanges
Symbol
Exchange
Helsinki
As of 11:30 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

revenio group oyj (REG1V) Snapshot

Open
€14.55
Previous Close
€14.45
Day High
€14.58
Day Low
€14.06
52 Week High
04/1/14 - €17.20
52 Week Low
01/8/14 - €11.32
Market Cap
113.4M
Average Volume 10 Days
11.4K
EPS TTM
€0.60
Shares Outstanding
7.9M
EX-Date
03/21/14
P/E TM
23.8x
Dividend
€0.30
Dividend Yield
2.10%
Current Stock Chart for REVENIO GROUP OYJ (REG1V)

Related News

No related news articles were found.

revenio group oyj (REG1V) Related Businessweek News

No Related Businessweek News Found

revenio group oyj (REG1V) Details

Revenio Group Oyj designs, manufactures, and sells medical instruments used for measuring intraocular pressure and bone density. The company operates in two segments: Revenio Health Tech and Revenio Technology and Services. The Revenio Health Tech segment designs, manufactures, and sells tonometers and disposable probes, and bone density measurement devices. The Revenio Technology and Services segment offers software for indoor logistics automation systems; manufactures and sells rigid inflatable boats; and provides contact center services. The company is headquartered in Vantaa, Finland.

74 Employees
Last Reported Date: 10/21/14

revenio group oyj (REG1V) Top Compensated Officers

Chief Executive Officer, President and Branch...
Total Annual Compensation: €226.3K
Compensation as of Fiscal Year 2013.

revenio group oyj (REG1V) Key Developments

Revenio Group Corporation Reports Earning Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for 2014

Revenio Group Corporation reported earning results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported net sales of EUR 5.0 million compared to EUR 4.5 million for the same period a year ago. Operating profit from continuing operations was EUR 1.1 million compared to EUR 1.2 million last year. Pre-tax profit from continuing operations was EUR 1.2 million compared to EUR 1.1 million last year. Net profit from continuing operations was EUR 0.8 million compared to EUR 0.8 million last year. Net loss was EUR 0.7 million compared to net profit of EUR 1.1 million last year. Net loss attributable to parent company shareholders was EUR 0.7 million compared to loss of EUR 1.1 million last year. For the nine months, the company reported net sales of EUR 15.4 million compared to EUR 14.5 million for the same period a year ago. Operating profit from continuing operations was EUR 3.4 million compared to EUR 3.5 million last year. Pre-tax profit from continuing operations was EUR 3.6 million compared to EUR 3.4 million last year. Net profit from continuing operations was EUR 2.8 million or EUR 0.36 per diluted share compared to EUR 2.3 million or EUR 0.29 per diluted share last year. Net profit was EUR 1.5 million compared to EUR 3.0 million last year. Net profit attributable to parent company shareholders was EUR 1.5 million compared to EUR 3.0 million last year. EBITDA was EUR 3.9 million against EUR 3.9 million a year ago. ROE was 13.6% against 26.2% a year ago. Cash flow from operating activities was EUR 1.0 million compared to EUR 3.1 million last year. Purchase of intangible assets was EUR 0.5 million against EUR 0.3 million a year ago. The group's financial guidance for 2014 remains unchanged: the net sales and operating profit of continuing operations exclusive of non-recurring items are expected to see year-on-year growth. Growth will focus on the Health Tech segment. The growth risks in the Technology and Services segment have increased due to financial uncertainty.

Revenio Group Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Reaffirms Group Earnings Guidance for the Year 2014

Revenio Group Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the six months, the company reported net sales from continuing operations were €13 million against €12.7 million a year ago. EBITDA from continuing operations were €2.9 million against €2.9 million a year ago. Operating profit from continuing operations were €2.6 million against €2.6 million a year ago. Pretax profit from continuing operations were €2.6 million against €2.6 million a year ago. Net profit from continuing operations were €2.3 million against €1.9 million a year ago. Diluted earnings per share from continuing operations were €0.30 against €0.24 a year ago. Gross capital expenditure was €0.6 million against €0.3 million a year ago. Return on equity was 30.9% against 25.1% a year ago. Cash flow from operating activities was €1.1 million against €2.7 million a year ago. Net profit attributable to parent company shareholders was €2.2 million against €1.9 million a year ago. Dilution-adjusted earnings per share for continuing and discontinued operations during the period were €0.29 against €0.24 a year ago. Purchase of property, plant and equipment was €0.1 against €0.3 million a year ago. Purchase of intangible assets was €0.5 against €0.0 million a year ago. These investments were concentrated primarily on product development. For the quarter, the company reported net sales were €6.8 million against €6.4 million a year ago. Operating profit from continuing operations was €1.4 million against €1.5 million a year ago. Pretax profit from continuing operations was €1.4 million against €1.4 million a year ago. Net profit from continuing operations was €1.3 million against €1.0 million a year ago. Net profit attributable to parent company shareholders was €1.2 million against €1.0 million a year ago. The group announced financial guidance for the year 2014 remain unchanged. Net sales and operating profit of continuing operations exclusive of non-recurring items are expected to see year-on-year growth. The biggest growth is seen in the Health Tech segment. The risks posed by growth in the Technology and Services segment have increased due to economic uncertainty.

Revenio Technology and Services Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Revenio Technology and Services announced unaudited earnings results for the second quarter and six months ended June 30, 2014. The company recorded net sales of €3.2 million, an increase of 1.8% compared to €3.1 million in the second quarter of 2013. Operating profit increased substantially and was €0.5 million against €0.4 million, growing by 53.3% year-on-year. The operating result was significantly affected by the measures taken to increase the production efficiency of the Rigid Inflatable Boats business and the increased profitability obtained by these actions. For the six months, the company reported net sales were €5.8 million against €6.4 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REG1V:FH €14.30 EUR -0.15

REG1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for REG1V.
View Industry Companies
 

Industry Analysis

REG1V

Industry Average

Valuation REG1V Industry Range
Price/Earnings 22.5x
Price/Sales 4.2x
Price/Book 8.1x
Price/Cash Flow 31.4x
TEV/Sales 4.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REVENIO GROUP OYJ, please visit www.revenio.fi. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.